CD19 and CD22 are essential B-cell receptors involved in modulating B-cell receptor (BCR) signaling and are widely exploited as therapeutic targets in B-cell acute lymphoblastic leukemia (B-ALL). This evidence concerns the gene CD22 and acute lymphoblastic leukemia.